GDF15 and cancer: A subsequent phase 1b study evaluated the safety and preliminary efficacy of ponsegromab in patients with advanced solid tumours who met Fearon’s criteria for cancer cachexia [2] and exhibited elevated serum GDF-15 concentrations (≥1500 pg/mL) [90].